New genetic study identifies neurological mechanisms as key drivers of chronic cough
The study included almost 30,000 individuals experiencing chronic cough from multiple population health resources including the UK Biobank, EXCEED Study, the Copenhagen Hospital Biobank, Genes & Health and the eMERGE Network.
As the largest and most diverse genetic study of chronic cough to date, researchers uncovered genes involved in neuronal signalling and sensory pathways, revealing a neurological basis for the condition.
The findings advance understanding of cough reflex hypersensitivity as a nervous system-mediated process and open up opportunities for the development of new targeted treatments.
Additionally, the study revealed shared genetics between chronic cough and chronic pain, suggesting shared neurological mechanisms. This insight offers a promising foundation for future research studies and could help inform effective strategies for managing both conditions.
Dr. Kayesha Coley, from the University of Leicester's Genetic Epidemiology group, who led the study, said, 'Our study represents a major step forward for understanding the biological mechanisms underlying the condition, and we hope it will inform future drug developments.'
Chronic cough can severely impact quality of life, often causing fatigue, breathlessness, disturbed sleep, and emotional distress. For many, it becomes a debilitating condition that disrupts everyday life and social interactions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
a day ago
- Zawya
Musk's Neuralink to test brain chips in clinical study in Great Britain
Elon Musk's brain implant company Neuralink said on Thursday it will launch a clinical study in Great Britain to test how its chips can enable patients with severe paralysis to control digital and physical tools with their thoughts. The company is partnering with the University College London Hospitals trust and Newcastle Hospitals to conduct the study, it said in a post on X. Neuralink said patients living with paralysis due to conditions such as spinal cord injury and a nervous system disease called Amyotrophic Lateral Sclerosis (ALS) qualify to participate in the study. The company raised $650 million in its latest funding round last month. It began human trials in 2024 on its brain implant after resolving safety concerns flagged by the U.S. Food and Drug Administration, which had initially rejected Neuralink's application in 2022. According to the company, five patients with severe paralysis are currently using its device to control digital and physical tools with their thoughts. Neuralink, founded in 2016, has raised about $1.3 billion from investors and is valued at roughly $9 billion, according to media reports, citing PitchBook. (Reporting by Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)
Emirates 24/7
2 days ago
- Emirates 24/7
New genetic study identifies neurological mechanisms as key drivers of chronic cough
A team at the University of Leicester, working with researchers from the University of Copenhagen and Queen Mary University of London, has conducted the first study of its kind to investigate the genetics of chronic cough. Their findings were published in the European Respiratory Journal. The study included almost 30,000 individuals experiencing chronic cough from multiple population health resources including the UK Biobank, EXCEED Study, the Copenhagen Hospital Biobank, Genes & Health and the eMERGE Network. As the largest and most diverse genetic study of chronic cough to date, researchers uncovered genes involved in neuronal signalling and sensory pathways, revealing a neurological basis for the condition. The findings advance understanding of cough reflex hypersensitivity as a nervous system-mediated process and open up opportunities for the development of new targeted treatments. Additionally, the study revealed shared genetics between chronic cough and chronic pain, suggesting shared neurological mechanisms. This insight offers a promising foundation for future research studies and could help inform effective strategies for managing both conditions. Dr. Kayesha Coley, from the University of Leicester's Genetic Epidemiology group, who led the study, said, 'Our study represents a major step forward for understanding the biological mechanisms underlying the condition, and we hope it will inform future drug developments.' Chronic cough can severely impact quality of life, often causing fatigue, breathlessness, disturbed sleep, and emotional distress. For many, it becomes a debilitating condition that disrupts everyday life and social interactions.
Zawya
5 days ago
- Zawya
Vinmec Central Park Performs Vietnam's First SEEG using AutoGuide Robotic Guidance System for a child diagnosed from refractory epilepsy
HO CHI MINH CITY, VIETNAM - Media OutReach Newswire - 29 July 2025 – A major breakthrough in Vietnam's neurological treatment was recently achieved as doctors at Vinmec Central Park International Hospital successfully performed surgery on a 9-year-old boy with drug-resistant epilepsy, utilizing the AutoGuide™ robotic Guidance system for SEEG implantation. This marks the first time in Vietnam that robotic guidance has been used in pediatric epilepsy surgery, — a milestone that opens new possibilities for safer, less invasive, and highly precise treatment options for vulnerable patients. The case also highlights Vietnam's progress in approaching global standards in advanced epilepsy care. A 5-Year Search for Seizure-Free Sleep The patient, B.Q.K. (age 9, from Hanoi), began experiencing seizures in 2021. Despite various treatment regimens and adjustments both domestically and abroad, his condition failed to improve - sometimes experiencing dozens of seizures per day. For nearly five years, his family sought treatment at numerous medical centers in the hope of giving their child a peaceful night's sleep without seizures. According to the World Health Organization (WHO), approximately 30% of epilepsy patients are drug-resistant (1), meaning they do not respond to medication. For these patients, surgery resection of the epileptic zone is often the most effective option. However, accurately localizing the epileptogenic zone - especially in children - is extremely challenging when scalp EEG, MRI, or PET scans provide inconclusive findings. SEEG and AutoGuide: A Technological Duo to Precisely Locate the "Culprit" in the Brain Following a thorough multidisciplinary evaluation, doctors at Vinmec Central Park decided to use AutoGuide™ robotic navigation system to perform stereo-electroencephalography (SEEG) to accurately identify the epileptic zone. The robotic guidance ensured high accuracy, faster operative time, and reduced trauma to the brain. After seven days of SEEG monitoring, the epileptogenic zone was localized in the right orbitofrontal cortex and inferior frontal gyrus—areas densely packed with neural pathways and blood vessels. On June 17, 2025, the epileptic zone removal was performed by Dr. Truong Van Tri and his team at Vinmec Central Park, with technical support from Assoc. Prof. Dr. Shunsuke Nakae, an epilepsy specialist from Japan. The surgery was successful, with no postoperative neurological deficits. After more than one month of recovery, the patient resumed normal activities and play, with only two minor nocturnal seizures recorded - a reduction of over 95% compared to preoperative frequency. " For the first time, we achieved near-perfect outcome in pediatric epilepsy surgery thanks to AutoGuide™. This is a critical milestone, especially for young patients who are highly vulnerable to major brain surgery," said Dr. Tri. Vinmec: Advancing Neurology with Technology and International Integration This successful case exemplifies Vinmec's strategy to build centers of medical excellence through the integration of advanced technology, multidisciplinary expertise, and individualized treatment protocols. Vinmec has been ranked as the No.1 private hospital system in Vietnam for expatriates and international visitors, according to independent patient satisfaction surveys. Vinmec Central Park is currently one of the few healthcare facilities in Vietnam, placing Vietnam among the few countries in Asia to master this technique—narrowing the gap with global neurology leaders. (1) Hashtag: #Vinmec The issuer is solely responsible for the content of this announcement. About Vinmec Health System Vinmec is a nonprofit healthcare system founded by Vingroup, one of Vietnam's largest private conglomerates. With 9 international hospitals and 4 international clinics nationwide, Vinmec is committed to delivering international-standard healthcare through subspecialized care, personalized treatment, and cutting-edge medical technology. Vinmec Central Park in Ho Chi Minh City is the flagship hospital in the network and has been widely recognized as the top private hospital in Vietnam for expatriates and international patients, serving tens of thousands annually. The hospital excels across several specialties: Neurosurgery & Epilepsy: SEEG, robotic-guided surgery, brain tumor resection Oncology – Orthopedic Surgery – Cardiology – Advanced Obstetrics & Gynecology Allergy & Clinical Immunology: Vietnam's first and only center recognized as a Center of Excellence by the World Allergy Organization (WAO), in close partnership with Cleveland Clinic (USA) to develop precision medicine and chronic disease management programs 3D Medical Technology: Pioneer in 3D-printed titanium implants for complex orthopedic oncology reconstructions Vinmec
